Key Dates

Related Announcements

RFA-HL-23-008 - NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

RFA-HL-23-009 - NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

PAR-20-128 - SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, Clinical Trial Not Allowed)

PAR-20-129 - SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)

PAR-20-130 - SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required) 

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

This NHLBI Notice clarifies the policy regarding concurrent applications submitted to the SBIR/STTR Commercialization Readiness Pilot (CRP) Program (SB1) and the Phase IIB SBIR Bridge (RFA-HL-23-009: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)) and Small Market (RFA-HL-23-008: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)) RFAs.

Additionally, this Notice informs potential applicants that NHLBI has posted a set of responses to Frequently Asked Questions (FAQs) | Seed (nih.gov), regarding RFA-HL-23-009 and RFA-HL-23-008 (FAQ #13).

Concurrent Submissions to CRP and RFA-HL-23-009 or RFA-HL-23-008 Not Allowed:

Applications for a CRP award and applications to either the NHLBI Phase IIB Bridge RFA (RFA-HL-23-009: NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)) or Small Market RFA (RFA-HL-23-008: NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)) that are associated with the same Phase II SBIR grant or contract award are not allowed to be under review at the same time, even if the applications are scientifically distinct.

All related FAQs are available online at the following link: Frequently Asked Questions (FAQs) | Seed (nih.gov). Applicants are strongly encouraged to review the FAQs, which may be updated at any time without additional notice, prior to submitting their application.

This Notice does not impact the following policies, which are not changed and still apply:

Notice of Clarification of SB1 Resubmission/Submission Policy (NOT-OD-21-027)

NIH/AHRQ Application Submission/Resubmission Policy (NOT-OD-18-197)

Policy and New Time Limit for NIH Resubmission Applications (NOT-OD-140).

Inquiries

Please direct all inquiries regarding this Notice to:

NHLBI Innovation and Commercialization (I&C) Office
Email : nhlbi_sbir@mail.nih.gov